Document Detail

A risk-benefit assessment of vigabatrin in the treatment of neurological disorders.
MedLine Citation:
PMID:  8037889     Owner:  NLM     Status:  MEDLINE    
Vigabatrin was designed to increase the levels of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the brain. It does this by replacing GABA as a substrate for the action of the catabolic enzyme GABA-transaminase. As a result of this inhibition, neuronal GABA levels are elevated, resulting in enhanced endogenous GABA transmission. A number of clinical trials assessing the effect of vigabatrin in epilepsy have been completed. Vigabatrin is of proven benefit in partial seizures and secondarily generalised tonic clonic seizures, and it is licensed for use as adjunctive therapy in these conditions in several European countries. It has been shown to be effective in some epilepsy syndromes in children including West's syndrome, infantile spasms and cryptogenic partial seizures. Its effect on primary generalised tonic clonic seizures is variable, while there is considerable evidence that it has a deleterious effect on myoclonic and absence seizures. There have been a few reports of the benefits of vigabatrin in other neurological disorders including tardive dyskinesia, degenerative ataxias and GABA metabolism disorders. The adverse effects associated with vigabatrin are similar to those seen with other anticonvulsants, with a predominance of CNS effects including somnolence, fatigue, irritability, dizziness and headache. Psychiatric symptoms including depression and psychosis are seen in a small number of patients and cause the most problems. These often necessitate discontinuation of vigabatrin, which usually results in resolution of symptoms.
J Srinivasan; A Richens
Related Documents :
1320519 - Determining the prognosis of childhood epilepsies by establishing immune abnormalities.
6660339 - A narcissistic reaction in a six-year-old girl with a seizure disorder.
19078729 - Dropped head presentation of mitochondrial myopathy.
11812539 - Pallidal administrations of gabazine and 5-ava affect pressure-induced behavioral disor...
6340959 - Automated analysis of abnormal electroencephalograms.
21750579 - Diras2 is associated with adult adhd, related traits, and co-morbid disorders.
8094599 - Csf somatostatin in obsessive-compulsive disorder.
17520339 - Uric acid changes in urine and plasma: an effective tool in screening for purine inborn...
20831459 - Positive experiences and quality of life in ménière's disorder.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drug safety     Volume:  10     ISSN:  0114-5916     ISO Abbreviation:  Drug Saf     Publication Date:  1994 May 
Date Detail:
Created Date:  1994-08-25     Completed Date:  1994-08-25     Revised Date:  2014-11-17    
Medline Journal Info:
Nlm Unique ID:  9002928     Medline TA:  Drug Saf     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  395-405     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
4-Aminobutyrate Transaminase / antagonists & inhibitors
Anticonvulsants / adverse effects*,  therapeutic use*
Brain / drug effects,  metabolism
Clinical Trials as Topic
Double-Blind Method
Epilepsy / drug therapy
Nervous System Diseases / drug therapy*
Risk Factors
Single-Blind Method
gamma-Aminobutyric Acid / adverse effects,  analogs & derivatives*,  therapeutic use
Reg. No./Substance:
0/Anticonvulsants; 56-12-2/gamma-Aminobutyric Acid; EC Transaminase; GR120KRT6K/Vigabatrin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clinically significant drug interactions with the oral anticoagulants.
Next Document:  Topical corticosteroids and unwanted local effects. Improving the benefit/risk ratio.